Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Major adverse cardiovascular events in cancer patients during and after treatment with immune checkpoint inhibitors
Nov 1, 2024
Clinical Studies - Nov 1, 2024 - Oct 31, 2027
Scheduled
Project leader: Daetwyler Eveline
Members: Scheler Eva, Kuster Gabriela M, Zippelius Alfred, Rothschild Sacha I
Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial.
Oct 31, 2024
Clinical Studies - Oct 31, 2024 - Dec 31, 2028
Ongoing
Project leader: Fischer Stefanie
Members: Dei Cas Alissa
AMG 355 20220028
Oct 17, 2024Eine Phase-1-Studie am Menschen zur Bewertung der Sicherheit, Verträglichkeit, Pharmakokinetik und Wirksamkeit von AMG 355 als Monotherapie und in Kombination mit Pembrolizumab bei Patienten mit fortgeschrittenen soliden Tumoren
Clinical Studies - Oct 17, 2024 - Dec 31, 2028
Ongoing
Project leader: Jörger Markus
Members: Donno Monica, Müller Fiona
SAKK 66/22 - Invincible 4 SAKK
Oct 17, 2024Protocol SAKK 66/22: Intratumoral INT230-6 followed by neoadjuvant immunochemotherapy in patients with early triple-negative breast cancer (TNBC). An openlabel randomized two-cohort phase 2 clinical trial. INVINCIBLE-4-SAKK
Clinical Studies - Oct 17, 2024 - Dec 31, 2029
Ongoing
Project leader: Jörger Markus
Members: Dei Cas Alissa, Müller Fiona
A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy
Oct 7, 2024
Clinical Studies - Oct 7, 2024 - Oct 9, 2028
Ongoing
Project leader: Schittenhelm Marcus
Members: Dei Cas Alissa
MS201924_0002
Sep 30, 2024An open-label, multicenter, randomized Phase 2 study of the ATR inhibitor tuvusertib in combination with the PARP inhibitor niraparib or the ATM inhibitor lartesertib in participants with BRCA mutant and/or homologous recombination deficiency (HRD) p...
Clinical Studies - Sep 30, 2024 - Sep 30, 2028
Ongoing
Project leader: Huober Jens
Members: Dei Cas Alissa, Müller Fiona
A first-in-human, open-label, multicenter Phase l/ll study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1)
Jun 13, 2024
Clinical Studies - Jun 13, 2024 - Dec 31, 2028
Ongoing
Project leader: Jörger Markus
Members: Sennhauser Andrina, Müller Fiona
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)
Apr 18, 2024
Clinical Studies - Apr 18, 2024 - Dec 31, 2028
Completed
Project leader: Hitz Felicitas
Members: Bürki Ramona, Quinter Janine
A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness (MO30039/MO43340)– The DANTE Trial A Trial of AIO in collaboration with SAKK
Apr 17, 2024
Clinical Studies - Apr 17, 2024 - Dec 31, 2028
Ongoing
Project leader: Weisshaupt Christian
Members: Müller Fiona, Kehl Jeanine
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Mar 25, 2024
Clinical Studies - Mar 25, 2024 - Dec 31, 2028
Ongoing
Project leader: Hess Dagmar
Members: Hutter Franziska, Quinter Janine
Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer with focus on digital side effect management. The MINERVA Trial – A phase IV Trial
Feb 29, 2024In der Minerva-Studie erhalten die Patientinnen das Medikament Abemaciclib entsprechend der Zulassung in Kombination mit einem Aromatasehemmer oder Fulvestrant als endokrine Therapie. Die Wahl der passenden endokrinen Therapie trifft der Prüfarzt/ di...
Clinical Studies - Feb 29, 2024 - Dec 31, 2028
Ongoing
Project leader: Huober Jens
Members: Radovanovic Suzana, Müller Fiona
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
Jan 26, 2024
Clinical Studies - Jan 26, 2024 - Dec 31, 2027
Ongoing
Project leader: Aeppli Stefanie
Members: Scherrer Julia, Quinter Janine
A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer.
Dec 21, 2023
Clinical Studies - Dec 21, 2023 - Dec 31, 2027
Ongoing
Project leader: Jörger Markus
Members: Quinter Janine, Radovanovic Suzana
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso)
Nov 17, 2023Forscher suchen nach einer besseren Möglichkeit, fortgeschrittenes Pleuramesotheliom zu behandeln. Pleuramesotheliom ist eine Krebsart, die die Lungenschleimhaut befällt. Fortgeschritten bedeutet in der Regel, dass der Krebs nicht operativ behandelt...
Clinical Studies - Nov 17, 2023 - Dec 31, 2028
Ongoing
Project leader: Früh Martin
Members: Demmer-Steingruber Ruth, Quinter Janine
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy
Nov 3, 2023
Clinical Studies - Nov 3, 2023 - Dec 1, 2028
Ongoing
Project leader: Baumann Michael
Members: Harder Anja, Quinter Janine
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Oct 30, 2023
Clinical Studies - Oct 30, 2023 - Dec 31, 2026
Ongoing
Project leader: Jörger Markus
Members: Bürki Ramona, Quinter Janine
A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents
Oct 18, 2023
Clinical Studies - Oct 18, 2023 - Dec 31, 2028
Ongoing
Project leader: Fischer Stefanie
Members: Harder Anja, Quinter Janine
Targeting des Immunoproteasoms in vivo
Aug 1, 2023Proteasome sind vielversprechende Angriffspunkte für Medikamente bei Krebserkrankungen. Mehrere Proteasom-Inhibitoren werden bereits klinisch zur Behandlung des multiplen Myeloms (MM) eingesetzt. Aktuelle in der Klinik eingesetzte Proteasom-Inhibitor...
Fundamental Research - Aug 1, 2023 - Dec 31, 2023
Automatically Closed
Project leader: Driessen Christoph
Members: Mendez Lopez Max, Besse Lenka
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects with Relapsed Small Cell Lung Cancer After Platinum-based First Line chemotherapy (DeLLphi-304)
Jul 17, 2023
Clinical Studies - Jul 17, 2023 - Dec 31, 2025
Ongoing
Project leader: Früh Martin
Members: Hutter Franziska, Quinter Janine
Retrospective and prospective registry of patients with metastatic NSCLC harboring typical and atypical EGFR mutations
Jul 3, 2023
Clinical Studies - Jul 3, 2023 - Dec 31, 2030
Ongoing
Project leader: Früh Martin
Members: Radovanovic Suzana, Müller Fiona